US Patent

US8637054 — Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives

Method of Use · Assigned to Laboratoires Thea SAS · Expires 2031-07-08 · 5y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a polymeric delivery system for a nonviscous prostaglandin-based ophthalmic solution without preservatives.

USPTO Abstract

This invention concerns an ophthalmic solution including: at least one prostaglandin; a solubilizing agent; a gelling agent of the carbomer type; a carbomer polymerization-inhibiting agent; a co-gelling/co-solubilizing agent.

Drugs covered by this patent

Xalatan (LATANOPROST) · Thea Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-446`	—	Xalatan

Patent Metadata

Patent number: US8637054
Jurisdiction: US
Classification: Method of Use
Expires: 2031-07-08
Drug substance claim: No
Drug product claim: Yes
Assignee: Laboratoires Thea SAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.